Navigation Links
Frost & Sullivan: Clinical Trial-based Evidence Vital to Obtain Venture Capital Funding for Wireless Patient Monitoring Technologies
Date:2/14/2013

afety regulations across different geographies could hinder widespread technology adoption.

Another major hurdle to the global uptake of WPM technology is the digital divide between the developed and developing countries. The lack of standardization of wireless data interfacing sensors and monitoring devices needs attention as soon as possible. Standardization among the different entities in the WPM market is necessary to improve interoperability among devices, choice of system assembly, and other related services.

Additionally, WPM companies need to back their technology with strong evidence-based clinical trials. It is important to document the technology's effectiveness, as investors need documented proof before investing.

"The WPM market needs to increasingly integrate evidence-based clinical trials and routine adoption of outcome measures as part of patient assessment," noted Mathew. "The pool of strong, positive data accumulated will encourage VCs to invest in WPM technologies."

The WPM system should have a simple user interface, be cost effective, and adhere to Health Insurance Portability and Accountability Act (HIPAA) laws for maintaining data security and health information confidentiality. Participants are also working toward providing an integrated suite of technologies including sensors, wireless infrastructure, user-friendly workflow process, collection of data in a central repository, and data analytics to use the accrued data to attract more investments.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.

Wireless Patient Monitoring Technologies—Evaluation of Funding Prospects, a part of the Technical Insights subscription, evaluates the funding prospects of the WPM marke
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
3. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
4. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
5. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
6. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... and research facility: Ampio Pharmaceuticals, 373 Inverness ... (720) 437-6500 Michael Macaluso , Ampio,s ... facility will be fully operational this summer, right ... Ampion TM necessary to accommodate the company,s BLA ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/22/2014)... TOKYO , July 23, 2014   ... Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a ... the company will be investing US$30 million in Remiges ... venture capital fund. Taiho has a long ... needs of oncologists and cancer patients. Our development of ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2
... Abbott (NYSE: ABT ) scientists and independent researchers ... Abbott,s investigational oncology compounds at this year,s American Society ... June 4-8 in Chicago . The presentations include ... and a humanized monoclonal antibody directed against CS1. Abbott,s oncology ...
... EAST HANOVER, N.J. , June 3 ... study of Afinitor® (everolimus) tablets plus best supportive care met ... or time without tumor growth, in patients with advanced pancreatic ... I n A dvanced N euroendocrine T ...
Cached Medicine Technology:Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting 7Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 2Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 3Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 4Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 5Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 6Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors 7
(Date:7/23/2014)... shown that some high-profile athletes who suffered repeated blows ... clumps in their brains. Those clumps suggest the athletes ... scientists are working on tests that might be able ... an article in Chemical & Engineering News (C&EN) ... Society. , In the article, Lauren Wolf, a senior ...
(Date:7/23/2014)... together for the first time to call for better ... worldwide suffering from the condition. , Psoriatic arthritis (PsA) ... damage if left untreated. , PsA tends to affect ... red, scaly rash, and affects approximately two per cent ... in five go on to develop PsA usually ...
(Date:7/23/2014)... Louis (PRWEB) July 23, 2014 Five years ... its doors there were few options for babies diagnosed with ... delivery, or travel across the country for innovative fetal therapies. ... Fetal Care Institute to care for their babies in the ... surgeries and interventions. , “A number of the babies ...
(Date:7/23/2014)... models of human oral cancer treated with an agent ... surrounding tissues, researchers from the School of Dentistry and ... Science Center at San Antonio found. The Health Science ... study, which is described in the journal Oral ... , Oral squamous cell carcinoma is the eighth most ...
(Date:7/23/2014)... July 23, 2014 SpaRoom® ... SpaRoom’s top product and premier diffuser, is now available ... and an improved motor for maximum quality. The new ... now available on SpaRoom.com for $60 along with the ... ultrasonic pulsations to create a long-lasting, tranquil mist. Add ...
Breaking Medicine News(10 mins):Health News:Psoriatic arthritis patients need better screening, warns panel of experts 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2
... to The Diabetes Research Institute of Miami on ... behalf of the motorcycle franchisee, ... check to The Diabetes Research Institute of Miami in honor ... the,leading voluntary insurer announced the motorcycle franchisee as its,100,000th Online ...
... epilepsy and depression, researchers say , , FRIDAY, ... deep brain stimulation sensor that can monitor levels ... Clinic researchers and colleagues. , The wireless instantaneous ... the brain to provide real-time measurement of chemicals ...
... Local Patients May Be at,Risk, PHILADELPHIA, Sept. 12 ... blood supply alert for New Jersey and,southeastern Pennsylvania., ... critical need for Type O,blood. Brigid O,Neill-LaGier, Chief Executive ... the community to donate blood. "The blood,supply is a ...
... reports a hiring trend over the past four months within High-Tech ... is has become a “recruiters” market causing both parties to change ... ... 2008 -- Lucas Group, an executive search firm, today reports a ...
... yearn to wear the sheer, body-hugging fashions available today, we ... dreaded back fat rolls and lumps. A study published in ... the official medical journal of the American Society of Plastic ... these unsightly bumps and bulges while hiding the scar under ...
... ATSI ), manufacturer and marketer of state-of-the-art ... unprecedented number,of scientific presentations and symposia will focus ... for Cardio-Thoracic Surgeons (EACTS),meeting. The EACTS is a ... and is being held in Lisbon, Portugal from ...
Cached Medicine News:Health News:Aflac Celebrates With Peterson's Harley Davidson of Miami as 100,000th Online Billing Customer 2Health News:American Red Cross Issues Local Blood Supply Alert 2Health News:American Red Cross Issues Local Blood Supply Alert 3Health News:Lucas Group Reports Hiring Trend in High-Tech Medical Device 2Health News:Say 'goodbye' to back fat rolls 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 2Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 3Health News:ATS Medical Products Featured Prominently in Scientific Presentations at European Association for Cardio-Thoracic Surgeons (EACTS) Annual Meeting 4
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: